SCHEMBL6210596

SCHEMBL6210596

Cc1nc2cc(Nc3nccc(NCc4ccccn4)n3)ccc2[nH]1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 2/20 0.47
KDM4E B2RXH2 2/20 0.44
PTK2 Q05397 4/20 0.44
PTK2B Q14289 2/20 0.44
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
TP53 P04637 1/20 0.43
HPGD P15428 1/20 0.43
HTT P42858 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
HSD17B10 Q99714 1/20 0.43
SYK P43405 5/20 0.41
IGF1R P08069 2/20 0.41
FGFR1 P11362 2/20 0.41
KDR P35968 2/20 0.41
PTPN11 Q06124 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
MAPT P10636 1/20 0.41
CYP2C9 P11712 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6210739 0.84 SYK (0.50) KCNH2KDM4EPTK2PTK2BNPC1
SCHEMBL6209413 0.83 QPCT (0.45) KCNH2KDM4EPTK2PTK2BNPC1
SCHEMBL6211926 0.82 PTK2 (0.59) PTK2PTK2BNPC1RAB9AIGF1R
SCHEMBL6216051 0.81 AURKA (0.61) KCNH2KDM4EPTK2PTK2BNPC1
SCHEMBL6260423 0.80 EGFR (0.51) KCNH2KDM4EPTK2PTK2BNPC1
SCHEMBL6212280 0.80 PTK2 (0.50) PTK2PTK2BIGF1RFGFR1KDR
SCHEMBL6259622 0.79 PTK2 (0.67) PTK2PTK2BSYKIGF1RFGFR1
SCHEMBL6258964 0.78 SYK (0.47) KCNH2KDM4EPTK2PTK2BNPC1
SCHEMBL6239489 0.77 KDR (0.57) KDM4EPTK2PTK2BNPC1RAB9A
SCHEMBL6210950 0.75 PTK2 (0.49) PTK2PTK2BIGF1RFGFR1KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1578732-A2 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH Pfizer Products Inc. (US) 2005-09-28 EP claimed
US-20040220177-A1 Compound for the treatment of abnormal cell growth PFIZER INC 2004-11-04 US claimed
WO-2004056786-A2 PYRIMIDINE DERIVATES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER PRODUCTS INC. (US) 2004-07-08 WO claimed
EP-1578732-A2 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH Pfizer Products Inc. (US) 2005-09-28 EP disclosed
US-20040220177-A1 Compound for the treatment of abnormal cell growth PFIZER INC 2004-11-04 US disclosed
WO-2004056786-A2 PYRIMIDINE DERIVATES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER PRODUCTS INC. (US) 2004-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220177-A1 Compound for the treatment of abnormal cell growth CCNA1, CCNB1, CCNT1 KCNH2 2765/4885KDM4E 2081/4885PTK2 3004/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.